Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OAT | P04181 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | ABAT | P80404 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16708925 | 1.00 | OAT (0.35) | OATCYP2C19GABRR1CYP1A2CYP2D6 | |
| SCHEMBL16699712 | 1.00 | OAT (0.35) | OATCYP2C19GABRR1CYP1A2CYP2D6 | |
| SCHEMBL23819355 | 0.83 | BTK (0.34) | OATCYP2C19GABRR1APLNR | |
| SCHEMBL23358844 | 0.82 | — | — | |
| SCHEMBL28389616 | 0.82 | — | — | |
| SCHEMBL22614330 | 0.80 | — | — | |
| SCHEMBL707201 | 0.80 | LMNA (0.39) | OATCYP2C19GABRR1GABRPGABRD | |
| SCHEMBL20772065 | 0.80 | — | — | |
| SCHEMBL22614543 | 0.80 | EPHX2 (0.31) | — | |
| SCHEMBL22614542 | 0.80 | EPHX2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543843-A1 | PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B | Denali Therapeutics Inc. (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119630634-A | Method for preparing modulators of eukaryotic initiation factor 2B | 戴纳立制药公司 | 2025-03-14 | — | — | CN | claimed |
| WO-2023250107-A1 | PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B | DENALI THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | claimed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4117780-B1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INT GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12441720-B2 | Modulators of the integrated stress response pathway | EVOTEC INTERNATIONAL GMBH (DE) | 2025-10-14 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3068785-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019046779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3068785-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | OAT 93/4885CYP2C19 115/4885GABRR1 1754/4885 |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | OAT 4255/4885CYP2C19 3588/4885GABRR1 3758/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | OAT 155/4885CYP2C19 419/4885GABRR1 1624/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | OAT 330/4885CYP2C19 914/4885GABRR1 1810/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | OAT 1227/4885CYP2C19 3991/4885GABRR1 1183/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | OAT 2069/4885CYP2C19 3737/4885GABRR1 1295/4885 |
| US-12441720-B2 | Modulators of the integrated stress response pathway | CRHR2, CRHR1, CRH | OAT 2217/4885CYP2C19 2370/4885GABRR1 1345/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | OAT 4255/4885CYP2C19 3588/4885GABRR1 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.